Compare NCPL & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCPL | PRFX |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 2.6M |
| IPO Year | 2022 | 2020 |
| Metric | NCPL | PRFX |
|---|---|---|
| Price | $0.74 | $1.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 33.9M | 245.5K |
| Earning Date | 03-19-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $869,460.00 | N/A |
| Revenue This Year | $739.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.21 | $0.58 |
| 52 Week High | $2.75 | $5.39 |
| Indicator | NCPL | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 63.81 | 53.01 |
| Support Level | $0.37 | $0.97 |
| Resistance Level | $0.84 | $1.20 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 52.34 | 40.21 |
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.